Clinical Trials on Amino Acids, Essential in Poland

Total 159 results

Andrea Gropman
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Longitudinal Study of Urea Cycle Disorders

Brain Diseases, Metabolic, Inborn | Amino Acid Metabolism, Inborn Errors | Urea Cycle Disorders

United States, Canada, Germany, Switzerland
BioMarin Pharmaceutical

Completed

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU (Prism-2)

Phenylketonuria (PKU)

United States
BioMarin Pharmaceutical

Completed

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Phenylketonuria

United States, Canada
BioMarin Pharmaceutical

Completed

PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry (PKUDOS)

Phenylketonuria | Hyperphenylalaninaemia

United States
Mark Batshaw
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Terminated

Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders

Urea Cycle Disorders

United States, Canada
Oregon Health and Science University

Completed

The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients (AltStim DBS)

Essential Tremor | Deep Brain Stimulation

United States
Swedish Orphan Biovitrum

Completed

Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care (OPAL)

Hereditary Tyrosinemia, Type I

Belgium, Denmark, France, Germany, Austria, Czechia, Finland, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden, United Kingdom
Academisch Medisch Centrum - Universiteit van Amsterdam...
Stichting Stofwisselkracht

Not yet recruiting

Exercise Intolerance Study in Long Chain Fatty Acid Oxidation Disorders (EXCITE LcFAOD)

Long-chain Fatty Acid Oxidation Disorders \(LC-FAOD\)

Netherlands
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Essential Hypertension

United States, Canada
Horizon Therapeutics, LLC

Completed

To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States, Canada
Rhode Island Hospital

Unknown

Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos

HIV | AIDS

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Recruiting

Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET (TREMBLE)

Central Nervous System Diseases | Essential Tremor | Deep Brain Stimulation | Magnetic Resonance | Diffusion Tensor Imaging

Netherlands
Kartos Therapeutics, Inc.

Recruiting

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)

United States, Mexico, Bulgaria, Poland, Russian Federation, Belarus, Georgia, South Africa, Ukraine
Idorsia Pharmaceuticals Ltd.

Completed

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

Essential Hypertension

United States, Canada, Israel, Puerto Rico
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Terminated

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Thailand, Malaysia, Korea, Republic of, Italy, United Kingdom, Poland, Germany, Turkey
Ohio State University Comprehensive Cancer Center
Incyte Corporation; Jazz Pharmaceuticals

Recruiting

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Secondary Acute Myeloid Leukemia | Myeloproliferative Neoplasm

United States
Disc Medicine, Inc

Recruiting

Study of DISC-0974 in Participants With Myelofibrosis and Anemia

Primary Myelofibrosis | Anemia | Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis | Myelofibrosis; Anemia | Myelofibrosis Due to and Following Polycythemia Vera

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

Urea Cycle Disorders

United States, Canada
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Urea Cycle Disorders

United States, Canada
Oregon Health and Science University
Portland VA Medical Center

Terminated

Ataxia in Essential Tremor: Describing the Differences Between Disease Process and Treatment Effect (ATAX)

Ataxia | Essential Tremor | Cerebellar Diseases | Deep Brain Stimulation

United States
AbbVie

Active, not recruiting

Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

Upper Limb Essential Tremor (UL ET)

United States, Canada
Horizon Therapeutics, LLC

Completed

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Urea Cycle Disorder

United States, Canada
Takeda

Completed

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Hypertension

Poland, Germany, Bulgaria, Russian Federation, Serbia, Sweden, Netherlands, Estonia, Slovakia, Finland
Menarini Group
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

Hypertension

Poland, Germany, Israel, Romania, Italy, Denmark, Czechia, Croatia
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Chile, Mexico
GlaxoSmithKline

Completed

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

Hypertension

United States
CTI BioPharma
PSI CRO

Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, Canada, Czechia, United States, Australia, France, Hungary, United Kingdom, Romania, Belarus, Bulgaria, Georgia, Germany, Israel, Italy, Poland, Russian Federation, Serbia, Ukraine, Bosnia and Herzegovina and more
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
Takeda

Completed

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Hypertension

United States, Mexico, Chile, Peru
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Russian Federation
Incyte Corporation

Terminated

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

MPN (Myeloproliferative Neoplasms)

United States
Jazz Pharmaceuticals

Active, not recruiting

A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

Essential Tremor

United States, Spain, Poland, Germany
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Ultragenyx Pharmaceutical Inc

Recruiting

A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Turkey, United Kingdom, Spain, Saudi Arabia, Poland, Czechia, Germany
Reneo Pharma Ltd

Completed

A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

Fatty Acid Oxidation Disorders

United States, France, Spain
Symplmed Pharmaceuticals LLC

Completed

Perindopril Amlodipine for the Treatment of Hypertension (PATH)

Essential Hypertension

United States
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Hypertension

United States
Katarzyna Siedzik

Completed

The Effect of a Meatless,Keto Restrictive Diet on Body Composition,Strength Capacity,Oxidative Stress,Immune Response

Glucose Metabolism Disorders | Body Weight | Insulin Resistance | Lipid Metabolism Disorders | Oxidative Stress | Insulin Sensitivity | Ketosis | Ketoses, Metabolic | Body Fat Disorder | Carbohydrate Metabolism Disorder | Somatic Disorders | Immunologic Factors | Trimethylamine N-oxide | Insulin Tolerance

Poland
Bayer

Completed

Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Hypertension

Germany, United States, Canada, Poland, United Kingdom, Belgium
Constellation Pharmaceuticals

Active, not recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
Daiichi Sankyo, Inc.

Completed

Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension

Essential Hypertension

France, Poland, Ukraine, Belgium, Germany, Spain, Bulgaria, Romania, Denmark, Russian Federation, Netherlands, Austria, Slovakia, Czechia
Kartos Therapeutics, Inc.

Recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis

United States, France, Australia, Spain, Germany, Bulgaria, Israel, Italy, Poland
Sankyo Pharma Gmbh

Completed

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension (OLMETREAT)

Essential Hypertension

France, Austria, Switzerland, Belgium, Germany, Italy, Netherlands, United Kingdom, Portugal
Cellaion SA

Terminated

HepaStem Long-Term Safety Registry (PROLONGSTEM)

Urea Cycle Disorder | Crigler-Najjar Syndrome | Acute on Chronic Liver Failure

Belgium, Spain, France, Bulgaria, Poland
Eli Lilly and Company

Completed

A Study of LY2623091 in Participants With High Blood Pressure

Primary Hypertension

United States, Puerto Rico, Canada
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
GlaxoSmithKline

Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

Neoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands

Clinical Trials on Amino Acids, Essential in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations